Veenstra DL - Search Results

1

The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation.

Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL. Li M, et al. Among authors: veenstra dl. J Genet Couns. 2019 Apr;28(2):477-490. doi: 10.1007/s10897-018-0286-9. Epub 2018 Dec 14. J Genet Couns. 2019. PMID: 30964586

2

A review of selected patient-generated outcome measures and their application in clinical trials.

Patel KK, Veenstra DL, Patrick DL. Patel KK, et al. Among authors: veenstra dl. Value Health. 2003 Sep-Oct;6(5):595-603. doi: 10.1046/j.1524-4733.2003.65236.x. Value Health. 2003. PMID: 14627066 Free article. Review.

3

Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?

Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Oestreicher N, et al. Among authors: veenstra dl. Genet Med. 2005 Jul-Aug;7(6):380-9. doi: 10.1097/01.gim.0000170776.31248.75. Genet Med. 2005. PMID: 16024969 Free article.

4

Ancillary risk information and pharmacogenetic tests: social and policy implications.

Henrikson NB, Burke W, Veenstra DL. Henrikson NB, et al. Among authors: veenstra dl. Pharmacogenomics J. 2008 Apr;8(2):85-9. doi: 10.1038/sj.tpj.6500457. Epub 2007 May 8. Pharmacogenomics J. 2008. PMID: 17486108 Review.

5

Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.

Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Veenstra DL, et al. Genet Med. 2007 Oct;9(10):695-704. doi: 10.1097/gim.0b013e318156dd07. Genet Med. 2007. PMID: 18073583 Free article.

6

Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review.

Jaja C, Burke W, Thummel K, Edwards K, Veenstra DL. Jaja C, et al. Among authors: veenstra dl. Community Genet. 2008;11(3):141-9. doi: 10.1159/000113876. Epub 2008 Mar 26. Community Genet. 2008. PMID: 18376110 Review.

7

Pharmacogenomics and public health.

Veenstra D, Burke W. Veenstra D, et al. Public Health Genomics. 2009;12(3):131-3. doi: 10.1159/000189624. Epub 2009 Feb 10. Public Health Genomics. 2009. PMID: 19204414 Free PMC article. No abstract available.

8

Stakeholder perspectives on a risk-benefit framework for genetic testing.

Roth JA, Garrison LP Jr, Burke W, Ramsey SD, Carlson R, Veenstra DL. Roth JA, et al. Among authors: veenstra dl. Public Health Genomics. 2011;14(2):59-67. doi: 10.1159/000290452. Epub 2010 Apr 20. Public Health Genomics. 2011. PMID: 20407215 Free PMC article.

9

A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.

Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. Veenstra DL, et al. Genet Med. 2010 Nov;12(11):686-93. doi: 10.1097/GIM.0b013e3181eff533. Genet Med. 2010. PMID: 20808229 Free PMC article.

10

Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support.

Overby CL, Tarczy-Hornoch P, Hoath JI, Kalet IJ, Veenstra DL. Overby CL, et al. Among authors: veenstra dl. BMC Bioinformatics. 2010 Oct 28;11 Suppl 9(Suppl 9):S10. doi: 10.1186/1471-2105-11-S9-S10. BMC Bioinformatics. 2010. PMID: 21044357 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

232 results

Search Page